Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLSE Stock Forecast 2025-2026
$17.91
Current Price
$1.30B
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLSE Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PLSE Price Momentum
+3.6%
1 Week Change
+7.9%
1 Month Change
+149.1%
1 Year Change
+0.7%
Year-to-Date Change
-28.4%
From 52W High of $25.00
+171.6%
From 52W Low of $6.60
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Pulse Biosciences (PLSE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PLSE and similar high-potential opportunities.
Latest PLSE Stock Price Targets & Analyst Predictions
PLSE has shown a year-to-date change of 0.7% and a 1-year change of 149.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PLSE. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLSE Analyst Ratings
0
Buy
0
Hold
0
Sell
PLSE Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $17.91
Latest PLSE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLSE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 21, 2022 | Maxim Group | Anthony Vendetti | Hold | Downgrade | $0.00 |
| May 13, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $0.00 |
| Apr 1, 2022 | Stephens & Co. | Chris Cooley | Overweight | Maintains | $12.00 |
| Apr 1, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.50 |
| Feb 10, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $20.00 |
| Nov 16, 2021 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $43.00 |
| Jul 27, 2021 | Stephens & Co. | Overweight | Initiates | $0.00 | |
| Mar 11, 2021 | Maxim Group | Buy | Initiates | $0.00 | |
| Jan 26, 2021 | HC Wainwright & Co. | Buy | Maintains | $40.00 | |
| May 12, 2020 | H.C. Wainwright | Buy | Upgrade | $0.00 | |
| May 12, 2020 | HC Wainwright & Co. | Buy | Upgrade | $16.00 | |
| Feb 14, 2020 | H.C. Wainwright | Neutral | Downgrade | $0.00 | |
| Feb 14, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Feb 25, 2019 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Feb 25, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 |
Pulse Biosciences Inc. (PLSE) Competitors
The following stocks are similar to Pulse Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PLSE
Pulse Biosciences
mkt cap
1.30B
Pulse Biosciences Inc. (PLSE) Financial Data
Pulse Biosciences Inc. has a market capitalization of $1.30B with a P/E ratio of -19.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -67.3%.
Valuation Metrics
Market Cap
$1.30B
Enterprise Value
$1.10B
P/E Ratio
-19.7x
PEG Ratio
-19.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
11.9x
Debt/Equity
7.7x
ROE
-67.3%
ROA
-36.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pulse Biosciences Inc. (PLSE) Business Model
About Pulse Biosciences Inc.
What They Do
Develops bioelectric medicine for medical treatments.
Business Model
The company utilizes its proprietary Nano-Pulse Stimulation technology to create innovative, non-thermal, and non-invasive treatment options primarily for dermatology and oncology. By focusing on these advanced medical solutions, it aims to deliver significant clinical benefits and generate revenue through product sales and partnerships in the healthcare sector.
Additional Information
Pulse Biosciences is positioned at the forefront of the medical technology landscape, contributing to personalized medicine and targeted treatment strategies. Its unique approach could revolutionize treatment paradigms in aesthetics, oncology, and dermatologic disorders, making it a notable player in the expanding field of bioelectric medical treatments.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
75
CEO
Mr. Paul Arthur LaViolette
Country
United States
IPO Year
2016
Website
www.pulsebiosciences.comPulse Biosciences Inc. (PLSE) Latest News & Analysis
Latest News
Quick Summary
Pulse Biosciences, Inc. granted equity inducement awards to five new employees outside its 2017 Equity Incentive Plan, under the 2017 Inducement Equity Incentive Plan.
Why It Matters
Pulse Biosciences' equity awards to new employees signal confidence in talent acquisition and long-term growth, potentially enhancing innovation and investor value.
Source: Business Wire
Market Sentiment:
Neutral
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
4 days ago
Quick Summary
Pulse Biosciences, Inc. (Nasdaq: PLSE) will report Q1 2025 financial results on May 8, 2025, after market close, followed by a conference call at 1:30 PM PT.
Why It Matters
Pulse Biosciences' upcoming financial results and conference call may impact stock performance, providing insights into company growth and technology advancements.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) will showcase its Nanosecond Pulsed Field Ablation technology at the Heart Rhythm Society 2025 Annual Meeting on April 24, including a live case transmission.
Why It Matters
Pulse Biosciences' technology showcase at a major medical conference can enhance visibility, attract partnerships, and drive stock performance, influencing investor sentiment and potential market value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences, Inc. (NASDAQ: PLSE) will hold its Q4 2024 earnings conference call on March 27, 2025, at 4:30 PM ET, featuring key company executives.
Why It Matters
Pulse Biosciences’ upcoming Q4 2024 earnings call could reveal key financial performance insights and strategic direction, influencing its stock value and investors' sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
1 month ago
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) reported positive preliminary results from its first-in-human study of Nanosecond Pulsed Field Ablation technology and shared Q4 and full-year 2024 financial results.
Why It Matters
Pulse Biosciences' positive study results for its innovative technology could indicate potential growth, affecting its stock value and attracting investor interest in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) will present at the 24th Annual Needham Virtual Health Care Conference on April 10, 2025, at 9:30 am ET. A webcast will be available online.
Why It Matters
Pulse Biosciences' presentation at a major health conference highlights its innovative technology, potentially increasing investor interest and influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PLSE Stock
What is Pulse Biosciences Inc.'s (PLSE) stock forecast for 2025?
Analyst forecasts for Pulse Biosciences Inc. (PLSE) are not currently available. The stock is trading at $17.91.
Is PLSE stock a good investment in 2025?
Analyst ratings for PLSE are not currently available. The stock is currently trading at $17.91. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLSE stock?
Price predictions from Wall Street analysts for PLSE are not currently available. The stock is trading at $17.91.
What is Pulse Biosciences Inc.'s business model?
The company utilizes its proprietary Nano-Pulse Stimulation technology to create innovative, non-thermal, and non-invasive treatment options primarily for dermatology and oncology. By focusing on these advanced medical solutions, it aims to deliver significant clinical benefits and generate revenue through product sales and partnerships in the healthcare sector.
What is the highest forecasted price for PLSE Pulse Biosciences Inc.?
Price targets from Wall Street analysts for PLSE are not currently available. The stock is trading at $17.91.
What is the lowest forecasted price for PLSE Pulse Biosciences Inc.?
Price targets from Wall Street analysts for PLSE are not currently available. The stock is trading at $17.91.
What is the overall PLSE consensus from analysts for Pulse Biosciences Inc.?
Analyst ratings for PLSE are not currently available. The stock is trading at $17.91.
How accurate are PLSE stock price projections?
Stock price projections, including those for Pulse Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:25 PM UTC